ORTHOPEDIATRICS CORP — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
OrthoPediatrics reported Q3 2026 revenue of $72.7M (up 19% YoY from $61.2M), with Trauma & Deformity up 19% and Scoliosis up 18%. Adjusted EBITDA reached $6.9M (vs. $6.2M prior year) and free cash flow turned positive at $1.6M. The company raised full-year 2026 revenue guidance to $270.0M–$273.0M (14–16% growth) from prior range of $265.0M–$269.0M, and reiterated expectations for ~$25.0M adjusted EBITDA and breakeven free cash flow for 2026.
Why this rating
Strong organic growth (19% YoY) and upward guidance revision demonstrate execution. Revenue uplift of ~$5M–$8M relative to prior guidance represents 1.4–2.2% of market cap; improving profitability and cash generation matter for a small-cap biomedical device company. Moderate materiality due to company size.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.